Dublin, Dec. 03, 2025 (GLOBE NEWSWIRE) — The “Drug Eluting Implants Market – Forecasts from 2025 to 2030” report has been added to ResearchAndMarkets.com’s offering.
The Drug Eluting Implants Market is forecasted to advance from USD 7.561 billion in 2025 to USD 10.133 billion by 2030, at a CAGR of 6.03%.
The global drug-eluting implants market is poised for significant growth, driven by their ability to deliver controlled-release active pharmaceutical ingredients (APIs) directly to targeted tissues, enhancing treatment efficacy while minimizing side effects.
These implants, notably drug-eluting stents (DES), outperform traditional oral or parenteral drug delivery methods and are increasingly adopted for managing conditions such as diabetes, cancer, contraception, HIV/AIDS prevention, chronic pain, cardiology, and central nervous system disorders. Key growth drivers include the rising prevalence of chronic diseases, an aging global population, and increased R&D investments. The market faces challenges from high development costs but benefits from growing patient adoption and technological advancements.
Market Drivers
Rising Prevalence of Diabetes
The global surge in diabetes cases is a major catalyst for the drug-eluting implants market. These implants are increasingly utilized for their healing properties in diabetes management, offering targeted drug delivery to improve patient outcomes. The International Diabetes Federation projects that the number of people with diabetes aged 20-79 will reach 700,002 by 2045, up significantly from previous years. This growing patient population is expected to drive demand for drug-eluting implants, as their precise delivery mechanisms support effective disease management, fueling market expansion through 2030.
Increasing Cancer Incidence
The rising global incidence of cancer significantly boosts the market for drug-eluting implants, particularly in chemotherapy applications. These implants provide a minimally invasive, image-guided parenteral route for drug administration, enhancing treatment precision. The increasing number of chemotherapy sessions worldwide, driven by growing cancer cases, underscores the demand for such implants. Their ability to deliver targeted therapies with reduced impact on healthy tissues positions them as a critical tool in oncology, further accelerating market growth during the forecast period.
Aging Population
The global geriatric population, projected by the United Nations to double to 1.5 billion by 2050, is a key driver. Older individuals are more prone to conditions requiring drug-eluting implants, such as cardiovascular diseases and cancer, increasing market demand. This demographic shift amplifies the need for advanced treatment options, positioning drug-eluting implants as a vital solution in addressing age-related health challenges.
Geographical Outlook
The Asia-Pacific region is expected to experience significant market growth, driven by its expanding geriatric population and rising prevalence of diabetes and cancer. North America and Europe continue to lead due to high adoption rates and advanced healthcare infrastructure, but Asia-Pacific’s rapid healthcare advancements and large patient base make it a high-growth region through 2030.
Competitive Landscape
Key players, including iVascular, ProMed Pharma, LLC, Johnson & Johnson, Boston Scientific Corporation, The Merck Group, Medtronic, Inc., Biosensors International Group, Abbott Laboratories, Elixir Medical Corporation, and Siemens Healthcare, are driving innovation through strategic partnerships and product development. For instance, in May 2023, iVascular received CE mark approval for its iCover balloon-expandable covered stent, enhancing vascular treatment options.
Market Outlook
The drug-eluting implants market is set for robust growth through 2030, propelled by rising chronic disease prevalence, an aging population, and R&D advancements. Asia-Pacific’s rapid expansion, alongside North America and Europe’s dominance, underscores the market’s global potential. Stakeholders must focus on innovation and scalability to meet growing demand while addressing cost-related challenges.
Key Benefits of this Report:
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
Report Coverage:
- Historical data from 2022 to 2024 & forecast data from 2025 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 148 |
| Forecast Period | 2025 – 2030 |
| Estimated Market Value (USD) in 2025 | $7.56 Billion |
| Forecasted Market Value (USD) by 2030 | $10.13 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
Company Profiling (Strategies, Products, Financial Information, and Key Developments)
- iVascular
- ProMed Pharma
- Boston Scientific Corporation
- Merck Group
- Medtronic, Inc.
- Biosensors International Group
- Abbott Laboratories
- Elixir Medical Corporation
- Biotronik SE & Co. KG
- Lubrizol
Market Segmentation:
By Product Type
- Drug Eluting Stents
- Contraceptive Implants
- Drug Eluting Vascular Grafts
- Others
By Material
- Biodegradable
- Non-Biodegradable
By Application
- Oncology
- Ophthalmology
- Cardiology
- Contraception/Birth Control
- Others
By End-User
- Hospital
- Ambulatory Surgical Centers
- Others
By Geography
- North America
- South America
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Thailand
- Taiwan
- Others
For more information about this report visit https://www.researchandmarkets.com/r/c9qxza
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Drug Eluting Implants Market
